Insights into the emerging immune checkpoint NR2F6 in cancer immunity

Abstract NR2F6 has emerged as a key player in immune regulation, especially in cancer immunity. It has indeed been reported that NR2F6 could suppress the anti-tumor immune response, and has therefore been suggested as possible target in cancer immunotherapy. In this review, we will start by describing the complex structure of the NR2F6 gene and its multifaceted biological functions. Then we will examine its expression in distinct immune cells and cancer cells, elucidating its role in cancer progression. Subsequently, we will highlight the predictive significance of NR2F6 for cancer patient outcome, suggesting its possible use as a prognostic biomarker. Finally, we will discuss the emerging potential of NR2F6 as a therapeutic target, presenting novel opportunities for the development of effective cancer immunotherapy strategies.